Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Fate Therapeutics, Inc. provides biotechnology services. The Company researches and develops therapies to repair and regenerate body tissues with the help of stem cells. Fate Therapeutics conducts business in the United States.
Website: fatetherapeutics.com



Growth: Good revenue growth rate 50.0%, there is acceleration compared to average historical growth rates 29.9%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 292.9%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.17 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 6.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 142.6% higher than minimum and 80.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -59.6x by EV / Sales multiple

Key Financials (Download financials)

Ticker: FATE
Share price, USD:  (-4.6%)1.65
year average price 1.1871  


year start price 1.2500 2025-05-20

min close price 0.9214 2025-08-08

max close price 1.9900 2026-05-14

current price 1.6500 2026-05-19
Common stocks: 96 629 106

Dividend Yield:  0.0%
EV / Sales: 15.7x
Margin (EBITDA LTM / Revenue): -1 292.9%
Fundamental value created in LTM:
Market Cap ($m): 159
Net Debt ($m): 61
EV (Enterprise Value): 220
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-13zacks.com

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

2025-10-28zacks.com

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

2025-08-12zacks.com

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

2025-06-12zacks.com

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?

2025-05-30globenewswire.com

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

2025-04-15zacks.com

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

2025-03-05zacks.com

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

2025-02-17zacks.com

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

2025-02-14globenewswire.com

Fate Therapeutics to Present at Upcoming Investor Conferences

2025-02-04seekingalpha.com

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2023-11-08 2023-08-08 2023-05-03 2022-11-03
acceptedDate 2025-11-13 08:35:02 2025-08-12 16:09:49 2025-03-05 16:03:44 2024-11-12 16:03:31 2024-08-13 16:08:07 2024-05-09 16:05:10 2024-02-26 16:10:56 2023-11-08 16:05:27 2023-08-08 16:09:52 2023-05-03 16:10:07 2023-02-28 16:06:30 2022-11-03 16:05:16 2022-02-28 16:13:07 2021-02-24 16:09:52
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 2M 2M 14M 3M 7M 2M 64M 2M 933 000 59M 96M 15M 56M 31M
costOfRevenue 0 0 0 0 35M 5M 157M 5M 0 0 14M 0 6M 126M
grossProfit 2M 2M 14M 3M -28M -3M -94M -3M 933 000 59M 83M 15M 50M -94M
grossProfitRatio 1 1 1 -4.11 -1.504 -1.438 1 1 1
researchAndDevelopmentExpenses 26M 27M 135M 35M 35M 27M 173M 34M 41M 66M 320M 80M 216M 126M
generalAndAdministrativeExpenses 11M 11M 74M 21M 17M 21M 81M 19M 23M 22M 84M 22M 57M 34M
sellingAndMarketingExpenses 0 0 0 0 0 0 15M 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 11M 11M 74M 21M 17M 21M 97M 19M 23M 22M 84M 22M 57M 34M
otherExpenses 0 0 15M 0 0 -1M -173M 1M 5M 6M -14M 0 -6M -126M
operatingExpenses 36M 39M 224M 55M 52M 48M 97M 53M 63M 88M 391M 101M 267M 34M
costAndExpenses 36M 39M 224M 55M 52M 53M 254M 53M 63M 88M 405M 101M 273M 160M
interestIncome 3M 3M 17M 4M 5M 4M 17M 5M 4M 4M 6M 2M 1M 2M
interestExpense 0 0 0 0 0 0 0 0 0 -10M 0 2M 0 0
depreciationAndAmortization 3M 3M 19M 0 5M 5M 18M 5M 4M 4M 14M 8M 6M 3M
ebitda -29M -31M -177M -52M -40M -46M -172M -51M -58M -24M -295M -79M -211M -125M
ebitdaratio -16.67 -16.147 -17.039 -5.96 -24.024 -26.378 -62.271 -0.414 -5.246
operatingIncome -35M -37M -210M -52M -45M -51M -191M -51M -63M -29M -308M -86M -217M -128M
operatingIncomeRatio -19.951 -19.385 -17.039 -6.657 -26.529 -26.378 -67.058 -0.485 -5.767
totalOtherIncomeExpensesNet 2M 3M 24M 5M 7M 3M 30M 6M 5M 10M 27M 3M 5M -45M
incomeBeforeTax -32M -34M -186M -48M -38M -48M -161M -45M -53M -19M -282M -84M -212M -173M
incomeBeforeTaxRatio -18.524 -17.866 -15.51 -5.674 -24.937 -23.236 -56.543 -0.32 -5.578
incomeTaxExpense 0 0 0 0 0 5M 0 -5M -4M -10M 0 -3M 0 0
netIncome -32M -34M -186M -48M -38M -48M -161M -45M -53M -9M -282M -81M -212M -173M
netIncomeRatio -18.524 -17.866 -15.51 -5.674 -24.937 -23.236 -56.543 -0.155 -5.389
eps -0.27 -0.29 -1.64 -0.4 -0.33 -0.47 -1.64 -0.46 -0.54 -0.094 -2.91 -0.83 -2.24 -2.1
epsdiluted -0.27 -0.29 -0.4 -0.33 -0.47 -0.46 -0.54 -0.094 -0.83
weightedAverageShsOut 119M 119M 114M 118M 117M 101M 98M 99M 98M 98M 97M 97M 95M 82M
weightedAverageShsOutDil 119M 119M 114M 118M 117M 101M 98M 99M 98M 98M 97M 97M 95M 82M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-05 2024-02-26 2023-02-28 2022-02-28 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 17M 17M 6M 1M 2M
ebit -196M -191M -308M -217M -128M
nonOperatingIncomeExcludingInterest -15M 0 0 0 0
netIncomeFromContinuingOperations -186M -161M -282M -212M -173M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -186M -161M -282M -212M -173M
epsDiluted -1.64 -1.64 -2.91 -2.24 -2.1

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2023-11-08 2023-08-08 2023-05-03 2022-11-03
acceptedDate 2025-11-13 08:35:02 2025-08-12 16:09:49 2025-03-05 16:03:44 2024-11-12 16:03:31 2024-08-13 16:08:07 2024-05-09 16:05:10 2024-02-26 16:10:56 2023-11-08 16:05:27 2023-08-08 16:09:52 2023-05-03 16:10:07 2023-02-28 16:06:30 2022-11-03 16:05:16 2022-02-28 16:13:07 2021-02-24 16:09:52
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 41M 41M 36M 38M 37M 121M 42M 33M 47M 42M 61M 82M 134M 167M
shortTermInvestments 175M 182M 243M 259M 268M 262M 273M 316M 331M 367M 375M 423M 482M 316M
cashAndShortTermInvestments 215M 223M 279M 297M 305M 384M 315M 350M 378M 409M 436M 505M 616M 483M
netReceivables 682 000 1M 4M 4M 1M 2M 2M 2M 3M 14M 38M 10M 9M 6M
inventory 0 0 0 0 -12M 0 0 1 0 0 0 0 0 0
otherCurrentAssets 5M 6M 9M 9M 13M 9M 900 000 13M 11M 15M 27M 20M 0 6M
totalCurrentAssets 221M 230M 292M 310M 319M 394M 332M 364M 392M 438M 502M 535M 633M 494M
propertyPlantEquipmentNet 102M 105M 111M 141M 147M 153M 159M 164M 170M 173M 66M 176M 162M 99M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 10M 26M 28M 34M 47M 23M 980 000 15M 7M 4M 5M 14M 101M 29M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 10M 10M 10M 10M 15M 9000 15M 9000 15M 15M 132M 24M 25M 9000
totalNonCurrentAssets 122M 141M 149M 185M 209M 176M 175M 180M 193M 192M 203M 214M 288M 128M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 344M 372M 441M 495M 529M 570M 506M 544M 585M 630M 706M 749M 921M 622M
accountPayables 4M 4M 9M 6M 5M 7M 5M 6M 8M 10M 8M 10M 9M 6M
shortTermDebt 5M 6M 0 7M 13M 6M 0 6M 6M 6M 0 6M 0 3M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 5000 0 393 000 600 000 0 159 000 0 1M 2M 2M 42M 35M 21M 21M
otherCurrentLiabilities 20M 19M 12M 24M 16M 32M 685 000 29M 29M 32M 40M 53M 3M 50M
totalCurrentLiabilities 28M 29M 39M 37M 35M 45M 39M 41M 45M 49M 114M 104M 81M 86M
longTermDebt 74M 76M 0 92M 94M 96M 0 99M 101M 102M 0 105M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 12M 27M 46M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 7M 6M 6M 3M 3M 3M 1M 701 000 2M 2M 4M 77M 25M 12M
totalNonCurrentLiabilities 81M 82M 83M 95M 97M 98M 99M 100M 102M 104M 108M 127M 161M 152M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 79M 81M 85M 99M 101M 96M 104M 105M 106M 108M 109M 111M 115M 94M
totalLiabilities 110M 110M 122M 133M 132M 144M 138M 141M 147M 153M 222M 231M 243M 238M
preferredStock 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000
commonStock 115 000 115 000 114 000 114 000 114 000 114 000 99 000 99 000 99 000 98 000 97 000 97 000 96 000 88 000
retainedEarnings -1 502M -1 470M -1 398M -1 346M -1 298M -1 260M -1 212M -1 168M -1 122M -1 070M -1 051M -994M -769M -557M
accumulatedOtherComprehensiveIncomeLoss 153 000 62 000 268 000 835 000 -422 000 -194 000 15 000 -499 000 -587 000 -646 000 -2M -3M -762 000 70 000
othertotalStockholdersEquity 1 736M 1 731M 1 707M 1 695M 1 686M 1 571M 1 561M 1 548M 1 516M
totalStockholdersEquity 234M 261M 319M 362M 397M 426M 368M 403M 438M 477M 484M 518M 679M 384M
totalEquity 234M 261M 319M 362M 397M 426M 368M 403M 438M 477M 484M 518M 679M 384M
totalLiabilitiesAndStockholdersEquity 344M 372M 495M 529M 570M 544M 585M 630M 749M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 344M 372M 441M 495M 529M 570M 506M 544M 585M 630M 706M 749M 921M 622M
totalInvestments 185M 208M 271M 293M 315M 285M 274M 316M 338M 371M 380M 437M 583M 344M
totalDebt 79M 81M 85M 99M 101M 102M 104M 105M 106M 108M 109M 111M 115M 97M
netDebt 39M 40M 49M 61M 64M -19M 62M 72M 60M 66M 48M 29M -19M -70M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-05 2024-02-26 2023-02-28 2022-02-28 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 4M 2M 38M 9M 6M
otherReceivables 0 0 0 0 0
prepaids 0 14M 0 9M 0
totalPayables 9M 5M 8M 9M 6M
otherPayables 0 0 0 0 0
accruedExpenses 10M 28M 18M 42M 5M
capitalLeaseObligationsCurrent 7M 6M 6M 6M 0
capitalLeaseObligationsNonCurrent 78M 97M 104M 109M 94M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 716M 1 580M 1 536M 1 449M 941M
otherTotalStockholdersEquity 0 -0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2023-11-08 2023-08-08 2023-05-03 2022-11-03
acceptedDate 2025-11-13 08:35:02 2025-08-12 16:09:49 2025-03-05 16:03:44 2024-11-12 16:03:31 2024-08-13 16:08:07 2024-05-09 16:05:10 2024-02-26 16:10:56 2023-11-08 16:05:27 2023-08-08 16:09:52 2023-05-03 16:10:07 2023-02-28 16:06:30 2022-11-03 16:05:16 2022-02-28 16:13:07 2021-02-24 16:09:52
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -32M -34M -186M -48M -38M -48M -161M -45M -53M -19M -282M -84M -212M -173M
depreciationAndAmortization 3M 3M 19M -3M 5M 5M 18M 5M 4M 4M 14M 3M 6M 3M
deferredIncomeTax 0 0 0 0 0 0 0 -3M -3M 0 0 0 0 0
stockBasedCompensation 5M 7M 41M 12M 10M 11M 43M 10M 13M 11M 79M 19M 54M 31M
changeInWorkingCapital 504 000 73 000 -2M 3M -4M 614 000 19M -3M 14M 12M -35M 10M 2M -13M
accountsReceivables 713 000 1M -1M -2M -190 000 968 000 37M 1M 11M 25M -30M 3M -3M -6M
inventory 0 0 0 0 0 0 0 2M 0 0 0 0 0 0
accountsPayables 0 0 -2M 2M 320 000 -5M -29M -2M 0 -20M 14M 0 0 -2M
otherWorkingCapital -209 000 -937 000 816 000 4M -4M 4M 11M -4M 3M 8M -19M 7M 5M -6M
otherNonCashItems -716 000 -1M 5M 6M -4M 22M -52M -2M -4M -37M -24M -4M -13M 113M
netCashProvidedByOperatingActivities -24M -25M -123M -29M -32M -33M -132M -38M -28M -29M -248M -55M -163M -39M
investmentsInPropertyPlantAndEquipment -2M -1M -730 000 -495 000 -51 000 -86 000 -6M -565 000 -2M -3M -36M -9M -51M -5M
acquisitionsNet 0 0 0 0 0 0 0 -25M 0 0 0 0 0 0
purchasesOfInvestments -58M -51M -318M -65M -129M -86M -359M -102M -92M -114M -405M -102M -968M -277M
salesMaturitiesOfInvestments 81M 72M 331M 91M 75M 104M 478M 128M 128M 127M 607M 191M 695M 121M
otherInvestingActivites 3000 122 000 0 0 17M 25M 0 0 0
netCashUsedForInvestingActivites 21M 20M 25M -53M 17M 25M 33M 9M 80M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 -95M -662 000 95M 0 0 207 000 0
commonStockRepurchased 0 0 0 666 000 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2M 1M -961 000 2M 95M 0 0 0 1M
netCashUsedProvidedByFinancingActivities 2M 1M 0 1M 95M 0 58 000 207 000 1M
effectOfForexChangesOnCash 0 0 5M 0 0 0 50 000 0 0 0 0 0 0 -15M
netChangeInCash -627 000 -4M -6M -4M -84M 79M -19M -13M 5M -19M -72M 27M -34M 68M
cashAtEndOfPeriod 51M 51M 36M 48M 37M 121M 42M 49M 62M 57M 61M 97M 149M 167M
cashAtBeginningOfPeriod 51M 55M 42M 37M 121M 42M 61M 62M 57M 77M 134M 71M 183M 100M
operatingCashFlow -24M -25M -123M -29M -32M -33M -132M -38M -28M -29M -248M -55M -163M -39M
capitalExpenditure -2M -1M -730 000 -495 000 -51 000 -86 000 -6M -565 000 -2M -3M -36M -9M -51M -5M
freeCashFlow -27M -26M -124M -30M -32M -33M -138M -39M -31M -32M -284M -64M -214M -44M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-05 2024-02-26 2023-02-28 2022-02-28 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities 12M 113M 167M -324M -161M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 95M 85 000 9M 412M 282M
netCommonStockIssuance 95M 85 000 9M 412M 282M
commonStockIssuance 95M 85 000 9M 412M 282M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 5M 0 0 41M 490 000
netCashProvidedByFinancingActivities 100M 85 000 9M 453M 283M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2024 q1
2024-05-11 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-13 12:30 ET
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
2026-05-11 12:30 ET
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
2026-05-05 12:30 ET
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
2026-05-04 13:00 ET
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
2026-04-30 13:00 ET
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
2026-04-16 13:00 ET
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR ...
2026-04-09 ET
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
2026-03-18 ET
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
2026-03-03 ET
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
2026-02-26 ET
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
2025-12-08 ET
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
2025-11-25 ET
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
2025-11-13 13:30 ET
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
2025-10-26 ET
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
2025-10-14 ET
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
2025-08-25 ET
Fate Therapeutics to Present at Upcoming Investor Conferences
2025-08-12 ET
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
2025-07-08 ET
Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth
2025-06-11 ET
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
2025-05-30 ET
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
2025-05-28 ET
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
2025-05-20 ET
4 Stocks To Watch In The $47 Billion Cellular Therapeutics Market
2025-05-13 ET
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
2025-05-02 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-04-29 ET
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
2025-04-14 ET
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
2025-04-02 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-04-02 ET
Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine
2025-03-18 ET
Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom
2025-03-05 ET
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
2025-03-04 ET
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2025-02-14 ET
Fate Therapeutics to Present at Upcoming Investor Conferences
2025-02-04 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-01-03 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-12-09 ET
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
2024-12-03 ET
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-11-29 ET
Fate Therapeutics Announces Leadership Transition
2024-11-26 ET
Fate Therapeutics to Present at Upcoming December Investor Conferences
2024-11-18 ET
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
2024-11-18 ET
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
2024-11-12 21:01 ET
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
2024-11-09 18:30 ET
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
2024-11-08 21:01 ET
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
2024-11-04 21:01 ET
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-10-02 20:01 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-09-12 20:01 ET
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
2024-08-13 20:05 ET
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
2024-08-02 20:01 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-07-31 12:00 ET
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
2024-07-02 20:01 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-06-04 20:01 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-05-29 20:01 ET
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
2024-05-09 20:01 ET
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
2024-05-09 12:30 ET
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
2024-05-06 12:00 ET
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
2024-05-03 20:30 ET
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
2024-04-22 20:30 ET
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
2024-04-03 12:00 ET
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
2024-04-02 20:01 ET
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 12:44 ET
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
2024-03-19 12:44 ET
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
2024-03-05 21:01 ET
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-03-01 13:00 ET
Fate Therapeutics to Present at Upcoming March Investor Conferences
2024-02-26 21:01 ET
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-15 13:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
2024-02-02 21:01 ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 13:00 ET
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
2023-12-13 22:00 ET
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-08 21:01 ET
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
2023-10-25 12:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
2023-08-31 12:00 ET
Fate Therapeutics to Present at Upcoming September Investor Conferences
2023-08-08 20:01 ET
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
2023-07-28 12:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
2023-05-31 12:00 ET
Fate Therapeutics to Present at Upcoming June Investor Conferences
2023-05-03 20:01 ET
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
2023-04-24 12:00 ET
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
2023-03-03 21:01 ET
Fate Therapeutics to Present at Upcoming March Investor Conferences
2023-02-28 21:01 ET
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
2023-02-13 13:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
2023-01-06 01:00 ET
FATE Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Potential Securities Claims Against Fate Therapeutics, Inc.
2023-01-05 22:00 ET
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
2023-01-05 ET
FATE Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Potential Securities Claims Against Fate Therapeutics, Inc.
2022-12-13 13:00 ET
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
2022-12-12 12:30 ET
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
2022-12-10 19:46 ET
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
2022-12-10 15:00 ET
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
2022-11-07 13:00 ET
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
2022-11-04 20:01 ET
Fate Therapeutics to Present at Upcoming Investor Conferences
2022-11-03 20:01 ET
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
2022-11-03 13:00 ET
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
2022-10-24 20:01 ET
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
2022-10-05 12:00 ET
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
2022-09-02 12:00 ET
Fate Therapeutics to Participate at Upcoming September Investor Conferences
2022-08-09 12:00 ET
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells
2022-08-03 20:01 ET
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
2022-07-25 20:01 ET
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
2022-06-30 20:01 ET
Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
2022-06-28 11:00 ET
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies
2022-06-03 12:00 ET
Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
2022-05-06 20:01 ET
Fate Therapeutics to Present at Upcoming May Investor Conferences
2022-05-04 20:01 ET
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
2022-04-22 12:00 ET
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results
2022-03-02 21:01 ET
Fate Therapeutics to Present at Upcoming March Investor Conferences
2022-02-28 21:01 ET
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
2022-02-16 13:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
2022-02-02 13:00 ET
Fate Therapeutics to Present at Upcoming February Investor Conferences
2022-01-10 13:00 ET
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
2021-12-13 21:31 ET
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
2021-12-13 14:01 ET
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
2021-12-08 22:44 ET
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting
2021-11-11 13:00 ET
Fate Therapeutics to Present at Upcoming Investor Conferences
2021-11-09 14:00 ET
Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference
2021-11-04 20:01 ET
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
2021-11-04 13:01 ET
Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting
2021-10-25 12:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
2021-10-01 12:01 ET
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
2021-09-15 12:00 ET
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
2021-09-02 20:01 ET
Fate Therapeutics to Present at Upcoming Investor Conferences
2021-08-19 20:01 ET
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
2021-08-04 20:01 ET
Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
2021-08-04 12:00 ET
Fate Therapeutics Appoints Yuan Xu to its Board of Directors
2021-08-02 20:50 ET
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
2021-07-16 12:00 ET
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
2021-07-15 20:01 ET
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
2021-06-15 12:00 ET
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
2021-06-04 11:00 ET
Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting
2021-05-25 20:01 ET
Fate Therapeutics to Present at Upcoming Investor Conferences
2021-05-13 20:01 ET
Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia
2021-05-05 20:01 ET
Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress
2021-04-29 12:00 ET
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results
2021-04-27 20:31 ET
Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting
2021-03-25 11:00 ET
Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service
2021-03-08 12:00 ET
Fate Therapeutics to Present at Upcoming Investor Conferences
2021-02-24 21:01 ET
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress
2021-02-22 21:01 ET
Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2021-02-19 13:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results
2021-01-08 21:26 ET
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-01-06 05:30 ET
Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2021-01-04 21:01 ET
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
2020-12-06 15:05 ET
Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma
2020-12-04 21:01 ET
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma
2020-11-30 13:00 ET
Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting
2020-11-12 21:01 ET
Fate Therapeutics Announces Participation in Upcoming Investor Conferences
2020-11-05 21:01 ET
Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress
2020-11-05 13:00 ET
Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting
2020-11-02 12:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results
2020-10-15 12:00 ET
Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
2020-09-30 12:00 ET
Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
2020-09-04 12:00 ET
Fate Therapeutics Announces September Investor Events
2020-08-19 12:00 ET
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
2020-08-05 20:01 ET
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
2020-08-04 20:01 ET
Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
2020-07-29 20:01 ET
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
2020-07-14 12:00 ET
Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies
2020-07-09 12:00 ET
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
2020-06-11 20:01 ET
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-06-09 04:49 ET
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
2020-06-08 20:01 ET
Fate Therapeutics Announces Proposed Public Offering of Common Stock
2020-05-20 12:00 ET
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy
2020-05-11 20:01 ET
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress
2020-05-05 20:01 ET
Fate Therapeutics Announces Changes to its Board of Directors
2020-05-04 20:01 ET
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results
2020-04-28 20:30 ET
Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting
2020-04-02 20:46 ET
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
2020-04-02 20:45 ET
Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update
2020-03-02 21:01 ET
Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook
2020-02-26 13:00 ET
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results
2020-02-07 13:00 ET
Fate Therapeutics to Present at Upcoming Investor Conferences
2020-01-13 13:00 ET
Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood
2019-12-10 14:51 ET
Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting
2019-12-08 15:39 ET
Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy
2019-12-07 13:40 ET
Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs
2019-11-27 21:01 ET
Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
2019-11-14 21:01 ET
Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
2019-11-06 14:01 ET
Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting
2019-11-05 21:05 ET
Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress
2019-10-29 20:01 ET
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results
2019-09-30 12:00 ET
Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies
2019-09-18 20:01 ET
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2019-09-12 04:53 ET
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
2019-09-11 20:01 ET
Fate Therapeutics Announces Proposed Public Offering of Common Stock
2019-04-18 12:01 ET
Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development
2019-04-02 12:00 ET
Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment
2019-04-01 12:01 ET
Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting

SEC forms

Show financial reports only

SEC form 10
2026-05-13 12:34 ET
Fate Therapeutics published news for 2026 q1
SEC form 8
2026-05-13 12:32 ET
Fate Therapeutics published news for 2026 q1
SEC form 8
2026-05-13 12:32 ET
Fate Therapeutics published news for 2026 q1
SEC form 10
2026-02-26 09:07 ET
Fate Therapeutics published news for 2025 q4
SEC form 8
2026-02-26 09:04 ET
Fate Therapeutics published news for 2025 q4
SEC form 8
2026-02-26 09:04 ET
Fate Therapeutics published news for 2025 q4
SEC form 10
2025-11-13 08:35 ET
Fate Therapeutics reported for 2025 q3
SEC form 8
2025-11-13 08:32 ET
Fate Therapeutics published news for 2025 q3
SEC form 8
2025-11-13 08:32 ET
Fate Therapeutics reported for 2025 q3
SEC form 8
2025-10-27 11:00 ET
Fate Therapeutics published news for 2025 q3
SEC form 8
2025-10-27 11:00 ET
Fate Therapeutics published news for 2025 q3
SEC form 10
2025-08-12 20:09 ET
Fate Therapeutics reported for 2025 q2
SEC form 8
2025-08-12 20:07 ET
Fate Therapeutics published news for 2025 q2
SEC form 8
2025-08-12 20:07 ET
Fate Therapeutics reported for 2025 q2
SEC form 10
2025-05-13 16:03 ET
Fate Therapeutics reported for 2025 q1
SEC form 8
2025-05-13 16:02 ET
Fate Therapeutics published news for 2025 q1
SEC form 8
2025-05-13 16:02 ET
Fate Therapeutics reported for 2025 q1
SEC form 10
2025-05-13 00:00 ET
Fate Therapeutics reported for 2025 q1
SEC form 10
2025-03-05 16:03 ET
Fate Therapeutics reported for 2024 q4
SEC form 8
2025-03-05 16:02 ET
Fate Therapeutics published news for 2024 q4
SEC form 8
2025-03-05 16:02 ET
Fate Therapeutics reported for 2024 q4
SEC form 10
2025-03-05 00:00 ET
Fate Therapeutics reported for 2024 q4
SEC form 10
2024-11-12 16:03 ET
Fate Therapeutics reported for 2024 q3
SEC form 8
2024-11-12 16:01 ET
Fate Therapeutics published news for 2024 q3
SEC form 8
2024-11-12 16:01 ET
Fate Therapeutics reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Fate Therapeutics reported for 2024 q3
SEC form 10
2024-08-13 16:08 ET
Fate Therapeutics reported for 2024 q2
SEC form 8
2024-08-13 16:06 ET
Fate Therapeutics published news for 2024 q2
SEC form 8
2024-08-13 16:06 ET
Fate Therapeutics reported for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Fate Therapeutics reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Fate Therapeutics reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Fate Therapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Fate Therapeutics reported for 2024 q1
SEC form 10
2024-02-26 16:10 ET
Fate Therapeutics reported for 2023 q4
SEC form 8
2024-02-26 16:03 ET
Fate Therapeutics published news for 2023 q4
SEC form 8
2024-02-26 16:03 ET
Fate Therapeutics reported for 2023 q4
SEC form 10
2024-02-26 00:00 ET
Fate Therapeutics reported for 2023 q4
SEC form 10
2023-11-08 16:05 ET
Fate Therapeutics reported for 2023 q3
SEC form 8
2023-11-08 16:03 ET
Fate Therapeutics reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Fate Therapeutics reported for 2023 q3
SEC form 10
2023-08-08 16:09 ET
Fate Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:07 ET
Fate Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Fate Therapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Fate Therapeutics reported for 2023 q2
SEC form 6
2023-06-09 16:08 ET
Fate Therapeutics published news for 2023 q1
SEC form 6
2023-06-08 16:12 ET
Fate Therapeutics published news for 2023 q1
SEC form 6
2023-06-07 08:52 ET
Fate Therapeutics published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Fate Therapeutics reported for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Fate Therapeutics reported for 2023 q1
SEC form 6
2023-04-19 16:06 ET
Fate Therapeutics published news for 2023 q1
SEC form 10
2023-02-28 16:06 ET
Fate Therapeutics reported for 2022 q4
SEC form 6
2023-02-28 16:03 ET
Fate Therapeutics reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Fate Therapeutics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Fate Therapeutics reported for 2022 q4
SEC form 6
2023-01-05 17:04 ET
Fate Therapeutics published news for 2022 q4
SEC form 6
2022-11-07 13:21 ET
Fate Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 16:05 ET
Fate Therapeutics reported for 2022 q3
SEC form 6
2022-11-03 16:03 ET
Fate Therapeutics reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Fate Therapeutics reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Fate Therapeutics reported for 2022 q3
SEC form 10
2022-08-03 16:08 ET
Fate Therapeutics reported for 2022 q2
SEC form 6
2022-08-03 16:03 ET
Fate Therapeutics published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Fate Therapeutics reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Fate Therapeutics reported for 2022 q2
SEC form 6
2022-06-30 16:06 ET
Fate Therapeutics published news for 2022 q1
SEC form 6
2022-06-29 17:01 ET
Fate Therapeutics published news for 2022 q1
SEC form 6
2022-06-13 16:10 ET
Fate Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 16:16 ET
Fate Therapeutics reported for 2022 q1
SEC form 6
2022-05-04 16:06 ET
Fate Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Fate Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Fate Therapeutics reported for 2022 q1
SEC form 6
2022-04-25 16:03 ET
Fate Therapeutics published news for 2022 q1
SEC form 10
2022-02-28 16:13 ET
Fate Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 16:06 ET
Fate Therapeutics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Fate Therapeutics published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Fate Therapeutics published news for 2021 q4
SEC form 6
2021-12-14 17:28 ET
Fate Therapeutics published news for 2021 q3
SEC form 6
2021-11-04 16:59 ET
Fate Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 16:13 ET
Fate Therapeutics published news for 2021 q3
SEC form 6
2021-11-04 16:07 ET
Fate Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Fate Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Fate Therapeutics published news for 2021 q3
SEC form 10
2021-08-04 16:13 ET
Fate Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 16:05 ET
Fate Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 09:20 ET
Fate Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Fate Therapeutics reported for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Fate Therapeutics published news for 2021 q2
SEC form 6
2021-06-07 16:50 ET
Fate Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 16:07 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 16:01 ET
Fate Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Fate Therapeutics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-04-21 16:11 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-04-07 16:49 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-04-02 16:32 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-03-25 16:01 ET
Fate Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 16:09 ET
Fate Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 16:01 ET
Fate Therapeutics published news for 2020 q4
SEC form 6
2021-01-08 16:02 ET
Fate Therapeutics published news for 2020 q4
SEC form 6
2020-12-22 16:01 ET
Fate Therapeutics published news for 2020 q3
SEC form 6
2020-12-07 09:00 ET
Fate Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 16:07 ET
Fate Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 16:02 ET
Fate Therapeutics published news for 2020 q3